Imatinib Sandoz

Imatinib mesilate, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is employed in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor, targeting malignant cells that express BCR‑ABL, c‑KIT or PDGFR. It is indicated for patients with Philadelphia chromosome‑positive disease and is administered under medical supervision.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Imatinib Sandoz acts on tyrosine kinase‑driven malignancies, primarily chronic myeloid leukemia and gastrointestinal stromal tumor. - Chronic myeloid leukemia (CML): reduces proliferation of BCR‑ABL‑positive leukemic cells, leading to disease control. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT–driven tumor growth, improving progression‑free survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): suppresses leukemic blasts by blocking BCR‑ABL signaling.

Imatinib Sandoz may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea - Peripheral edema - Fatigue - Diarrhea Serious or Rare Side Effects: - Neutropenia or severe leukopenia - Hepatotoxicity (elevated liver enzymes) - Cardiac failure or reduced left‑ventricular function - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Imatinib Sandoz, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood counts: perform regular complete blood count (CBC) testing to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes before initiation and periodically during therapy. - Evaluate cardiac status: perform baseline and periodic echocardiograms in patients with cardiac risk factors. - Avoid in patients with known hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution during pregnancy: consider risk‑benefit assessment as safety data are limited. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Imatinib Sandoz can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels, risking toxicity. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce imatinib exposure, compromising effectiveness. Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect gastrointestinal absorption; separate dosing by at least 2 hours. - Warfarin: imatinib may enhance anticoagulant effect; monitor INR closely. - Live attenuated vaccines: potential reduced immune response; consider timing of vaccination.